---
title: "Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Prevalence"
description: "Formulary evidence on Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Prevalence. Topics: Global pooled prevalence in females: systematic review and meta-analysis, Worldwide prevalence per female births: reference estimates, Australia: point prevalence by age group, France: prevalence in females aged 4 to 15 years, and 5 further topics. 9 evidence topics quoted from 12 sources."
canonical: "https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description/prevalence"
published: "2026-11-15T20:23:41-05:00"
modified: "2026-11-15T20:23:41-05:00"
---

# Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Prevalence

<a id="heading-2.2.1.2.2"></a>

## 2.2.1.2.2 Prevalence of Rett syndrome

<a id="topic-2.2.1.2.2-1"></a>

### Global pooled prevalence in females: systematic review and meta-analysis

> “We conducted a search of PubMed, Embase, Web of Science, Cochrane Library, LILACS, and LIVIVO to retrieve studies published in English between Jan. 1, 2000, and June 30, 2021. Pooled prevalence with a 95% confidence interval (CI) was estimated using a random-effects meta-analysis based on a generalized linear mixed model with a logit link.”
> “Ten eligible studies were identified (all in females), with a combined sample size of 9.57 million women and 673 Rett syndrome cases. The pooled prevalence estimate (random effects) was 7.1 per 100,000 females (95% CI: 4.8, 10.5, heterogeneity p < 0.001). Despite greatly variable precision of estimation, all estimates were compatible with a prevalence range of approximately 5 to 10 cases per 100,000 females based on their respective 95% CIs.”
> “Study-specific prevalence estimates per 100,000 females (95% CI) ranged from 0.0 (0.0, 8.8) to 38.3 (4.6, 138.0), with a highly significant heterogeneity test (p < 0.001, I2 = 0.831).”
> “No studies that included patients with RTT older than 35 years were included.”

Source: [Petriti et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9841621/)

<a id="topic-2.2.1.2.2-2"></a>

### Worldwide prevalence per female births: reference estimates

> “The worldwide prevalence is 1:10,000-1:23,000 female births”

Source: [Kaur and Christodoulou (2025)](https://www.ncbi.nlm.nih.gov/books/NBK1497/)

> “Rett syndrome (RTT) is a severe neurodevelopmental disease that affects approximately 1 in 10,000 live female births”

Source: [Neul et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3058521/)

<a id="topic-2.2.1.2.2-3"></a>

### Australia: point prevalence by age group

> “The point prevalence of RTT in Australia on the 31st June 2009 was 8.6 per 100,000 females (95% CI 7.4-10.1) aged five to 18 years and 5.8 per 100,000 females (95% CI 4.8-6.9) aged 19 years to 32 years.”

Source: [Fehr et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3152673/)

> “The prevalence of RTT was .88 per 10,000 females in 5- to 18-year-olds”

Source: [Laurvick et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16615965/)

<a id="topic-2.2.1.2.2-4"></a>

### France: prevalence in females aged 4 to 15 years

> “The data presented here indicate a prevalence of Rett syndrome of 0.558 per 10,000 females aged 4-15 years in France.”

Source: [Bienvenu et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16647997/)

<a id="topic-2.2.1.2.2-5"></a>

### Serbia: prevalence in females younger than 19 years

> “We estimated the prevalence of RTT in population of females younger than 19 years at 1:8,439.”

Source: [Sarajlija et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25571926/)

<a id="topic-2.2.1.2.2-6"></a>

### United States: annual prevalence of diagnosis in claims data, 2016 to 2019

> “The annual prevalence of RTT between November 1, 2016 and October 31, 2019 in this dataset ranged from 0.30–0.32 per 10,000 enrollees overall, with higher prevalence ranges observed among female than male patients (female: 0.45–0.52; male: 0.08–0.10; Table 1).”
> “Annual prevalence was calculated as the proportion of patients with a diagnosis of RTT among the total number of patients enrolled in the IQVIA Dx and LRx databases.”

Source: [May et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10071755/)

<a id="topic-2.2.1.2.2-7"></a>

### United States, European Union, Japan, Canada, and Israel: trofinetide manufacturer estimates

> “Based on 2024 claims data, we estimate that approximately 6,000 people are diagnosed with Rett Syndrome in the U.S. We estimate a prevalent population of 6,000 to 9,000 people in the U.S.”
> “In the European Union, where we estimate a prevalent population of 9,000 to 12,000 Rett syndrome patients, we filed our marketing authorization application (MAA) with the European Medicines Agency (EMA) in January 2025.”
> “In Japan, where we estimate a prevalent population of 1,000 to 2,000 Rett syndrome patients, we are conducting a small Phase 3 study to support a future JNDA to that regulatory agency.”
> “In Canada, where we estimate a prevalent population of 600 to 900 Rett syndrome patients, Health Canada granted marketing authorization of DAYBUE in October 2024. In Israel, where we estimate a prevalent population of about 200 Rett syndrome patients, the Ministry of Health in Israel granted marketing authorization of DAYBUE in December 2025.”

Source: [Acadia Pharmaceuticals Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1070494/000119312526072519/acad-20251231.htm)

<a id="topic-2.2.1.2.2-8"></a>

### United States, European Union, and United Kingdom: TSHA-102 sponsor estimate of the addressable population

> “The estimated addressable patient population with typical Rett syndrome caused by a pathogenic/likely pathogenic MECP2 mutation is between 15,000 and 20,000 patients in the United States, European Union and United Kingdom. Within the U.S. specifically, patient estimates range from 6,000 to 9,000 based on claims data and epidemiology data.”

Source: [Taysha Gene Therapies Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526115202/tsha-20251231.htm)

<a id="topic-2.2.1.2.2-9"></a>

### Canada: estimated and diagnosed prevalence

> “It is estimated to affect 1 in 10,000 females aged 12 years and younger, with a worldwide prevalence of 1 in 20,000 to 1 in 40,000”
> “According to the sponsor, in Canada, the estimated prevalence is between 600 and 900 cases, based on the extrapolation of US epidemiological data, and around 220 to 240 prevalent cases are diagnosed in Ontario annually, based on assessments of Institute for Clinical Evaluative Sciences datasets”

Source: [CDA-AMC trofinetide reimbursement review (2025)](https://canjhealthtechnol.ca/index.php/cjht/article/download/SR0829r/2969?inline=1)

> “In total, 246 RTT cases were indexed; 40% from central Ontario, 95% female, median age 21 years.”

Source: [Bond et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/41267498/)

## Related pages
- [Lonimecgene renparvovec (TSHA-102): Rett syndrome](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Terms and abbreviations](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/terms-and-abbreviations.md)
- [Lonimecgene renparvovec (TSHA-102): Rett syndrome](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/executive-summary.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Product information and disease description](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Clinical evidence](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/clinical-evidence.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Economic information and modeling report](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/economics) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/economics.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: References](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/references) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/references.md)
